3.08 Lif's opinion on medicine prices in Denmark
Lif finds it essential that medicine prices reflect the research and development activities. This is the only way to maintain the incentives for a continued development of future therapies.
The medicine prices in Denmark should also reflect the general level of prices and income.
Lif does not exert and cannot exert any influence on companies' pricing policies, but as a responsible player in the health sector Lif finds that the general level of medicinal prices in Denmark should not differ significantly from the level in other comparable European countries.
Lif believes:
- that the current reimbursement system will entail more frequent price adjustments and fluctuations as a result of fiercer price competition,
- that the terms of competition in the individual sub segments may lead to relatively large price fluctuations in both directions,
- that overall, prices will still fall due to the continued expiry of patents and the resulting competition from generic products.
|
Print
